GEN (Genetic Engineering & Biotech News)
scienceCenter
Lilly Looks Beyond Obesity with Up-to-$2.9B Acquisition of Merida Biosciencestranslating…
Based in Cambridge, MA, Merida develops biologic drugs that are engineered to selectively degrade pathogenic autoantibodies linked to a number of immune-mediated conditions. Merida has said its precision degradation approach aims to address the biological cause of these…
Keywords#Merida#Acquisition#Beyond#Beyond Obesity#Biosciences